KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Treasury Shares (2020 - 2025)

Historic Treasury Shares for Castle Biosciences (CSTL) over the last 4 years, with Q3 2025 value amounting to $3.9 million.

  • Castle Biosciences' Treasury Shares changed N/A to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year change of. This contributed to the annual value of $3.2 million for FY2024, which is N/A changed from last year.
  • Per Castle Biosciences' latest filing, its Treasury Shares stood at $3.9 million for Q3 2025.
  • Over the past 5 years, Castle Biosciences' Treasury Shares peaked at $3.9 million during Q3 2025, and registered a low of $1.1 million during Q4 2021.
  • In the last 3 years, Castle Biosciences' Treasury Shares had a median value of $3.2 million in 2024 and averaged $2.7 million.
  • Within the past 5 years, the most significant YoY rise in Castle Biosciences' Treasury Shares was 55035.52% (2021), while the steepest drop was 55035.52% (2021).
  • Over the past 3 years, Castle Biosciences' Treasury Shares (Quarter) stood at $1.1 million in 2021, then skyrocketed by 204.35% to $3.2 million in 2024, then grew by 22.37% to $3.9 million in 2025.
  • Its Treasury Shares stands at $3.9 million for Q3 2025, versus $3.2 million for Q4 2024 and $1.1 million for Q4 2021.